Hanall Biopharma (009420) — Free Cash Flow Generation Index
Hanall Biopharma (009420) has a Free Cash Flow Generation Index of 0.55x as of September 2025. Free cash flow of ₩4.07 Billion represents 1% of operating cash flow (₩7.34 Billion). Explore 009420 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Hanall Biopharma Free Cash Flow Generation Index (2011–2024)
Historical FCF Generation Index trend for Hanall Biopharma across 10 annual periods. For the full cash flow conversion analysis, see Hanall Biopharma (009420) cash conversion ratio.
Annual Free Cash Flow Generation for Hanall Biopharma (2011–2024)
Year-by-year Free Cash Flow Generation Index for Hanall Biopharma. Check 009420 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.46x | ₩-13.71 Billion | ₩9.36 Billion | ₩23.07 Billion | ▼ -312.3% |
| 2023 | 0.69x | ₩20.45 Billion | ₩29.64 Billion | ₩9.20 Billion | ▼ -0.8% |
| 2022 | 0.70x | ₩17.53 Billion | ₩25.20 Billion | ₩2.83 Billion | ▲ +107.2% |
| 2021 | -9.72x | ₩-8.16 Billion | ₩839.87 Million | ₩4.61 Billion | ▼ -39.8% |
| 2020 | -6.95x | ₩-6.46 Billion | ₩929.29 Million | ₩2.56 Billion | ▼ -1266.2% |
| 2019 | 0.60x | ₩12.22 Billion | ₩20.49 Billion | ₩2.12 Billion | ▼ -37.1% |
| 2017 | 0.95x | ₩39.93 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -53.1% |
| 2016 | 2.02x | ₩7.98 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +1.3% |
| 2012 | 1.99x | ₩4.38 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +88.6% |
| 2011 | 1.06x | ₩7.84 Billion | ₩7.41 Billion | ₩426.70 Million | — |